SCHEMBL31160897

SCHEMBL31160897

Cc1nccc2[nH]c(=O)n(CC(=O)O)c(=O)c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 3/20 0.40
GRIA2 P42262 3/20 0.40
GRIA3 P42263 3/20 0.40
GRIA4 P48058 3/20 0.40
GRIN2D O15399 2/20 0.40
GRIN3B O60391 2/20 0.40
GRIN1 Q05586 2/20 0.40
GRIN2A Q12879 2/20 0.40
GRIN2B Q13224 2/20 0.40
GRIN2C Q14957 2/20 0.40
GRIN3A Q8TCU5 2/20 0.40
KDM4E B2RXH2 6/20 0.37
ALDH1A1 P00352 4/20 0.37
HPGD P15428 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
AKR1B10 O60218 2/20 0.36
HSD17B10 Q99714 2/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31160911 0.86 KDM4E (0.43) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL31160924 0.72 DAO (0.44) GRIA1GRIA2GRIA3GRIA4GRIN2D
SCHEMBL31160768 0.72 FEN1 (0.60) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL4563757 0.72 KDM4E (0.45) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL7856502 0.69 ALDH1A1 (0.50) GRIA1GRIA2GRIA3GRIA4GRIN2D
SCHEMBL10084481 0.69 KDM4E (0.50) GRIA1GRIA2GRIA3GRIA4GRIN2D
SCHEMBL3315017 0.69 KDM4E (0.41) GRIN1GRIN2BKDM4EALDH1A1PTGDR2
SCHEMBL9981108 0.69 DAO (0.58) KDM4EALDH1A1HPGDSMN1; SMN2PDE3B
SCHEMBL31146143 0.69 PIM1 (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3311524 0.68 ALDH1A1 (0.73) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559464-B2 Quinazolinone dione compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2026-02-24 US disclosed
EP-4688756-A1 QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2026-02-11 EP disclosed
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 US disclosed
WO-2024206345-A1 QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, MYLK2 GRIA1 3559/4885GRIA2 3203/4885GRIA3 3464/4885
US-12559464-B2 Quinazolinone dione compounds and uses thereof TNNI3, TNNT2, TNNC1 GRIA1 1210/4885GRIA2 2128/4885GRIA3 1734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.